已收盘 04-18 16:00:00 美东时间
-0.730
-4.58%
新技术的发展,总是充满令人激动与失望的瞬间。 细胞疗法过去几年的发展便是如此。自然杀伤(NK)细胞疗法因其“通用现货”等优势,被寄予厚望。 作为先天免疫系统的一...
04-15 13:47
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today a...
04-04 19:30
Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinic...
04-01 19:00
近年来,医疗健康产业创新不断涌现,并发展成为最活跃的行业之一,36氪见证和陪伴着这一领域创新企业的成长,并为行业带来专业的声音。 为此,36氪推出了“医疗健康行...
03-26 09:07
Curis (NASDAQ:CRIS) reported quarterly losses of $(2.03) per share which beat the analyst consensus estimate of $(2.11) by 3.79 percent. This is a 13.62 percent increase over losses of $(2.35) per share from the same
02-08 21:01
Emavusertib data presented at ASH showed 3 of 5 patients achieved CR in R/R PCNSL Expansion of clinical sites in US and Europe in progress Cash runway into 2025 Management to host conference...
02-08 21:00
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
02-08 17:43
人工智能(AI)在生命科学领域产生了重大影响,不仅用于数据分析和药物研发,还应用于疾病诊断和治疗。经过评选活动,揭晓了2023年的十大创新产品,包括Orbit...
02-08 15:13